World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
129
Citations
58196
World Ranking
2612
National Ranking
1467

Overview

Vicente Valero is affiliated with The University of Texas MD Anderson Cancer Center in the United States. Their research focuses primarily on fields related to medicine, with a significant emphasis on oncology and cancer-related studies. They have contributed extensively to the understanding and treatment of breast cancer and related malignancies.

Their expertise includes multiple key subfields of study:

  • Oncology
  • Cancer Research
  • Radiology, Nuclear Medicine and Imaging
  • Pulmonary and Respiratory Medicine
  • Pathology and Forensic Medicine

Vicente Valero has published numerous papers across a variety of scientific venues, with a strong presence in journals known for advancing cancer research and clinical oncology. The most frequent publication venues include:

  • Cancer Research
  • Journal of Clinical Oncology
  • Clinical Cancer Research
  • Annals of Surgical Oncology
  • Cancers

Their recent papers illustrate a focus on breast cancer treatment and diagnostic techniques:

  • "Eliminating breast surgery for invasive breast cancer in exceptional responders to neoadjuvant systemic therapy: a multicentre, single-arm, phase 2 trial," 2022, The Lancet Oncology
  • "Adjuvant Trastuzumab Emtansine Versus Paclitaxel in Combination With Trastuzumab for Stage I HER2-Positive Breast Cancer (ATEMPT): A Randomized Clinical Trial," 2021, Journal of Clinical Oncology
  • "Accuracy of Post-Neoadjuvant Chemotherapy Image-Guided Breast Biopsy to Predict Residual Cancer," 2020, JAMA Surgery
  • "Final results of the double-blind placebo-controlled randomized phase 2 LOTUS trial of first-line ipatasertib plus paclitaxel for inoperable locally advanced/metastatic triple-negative breast cancer," 2021, Breast Cancer Research and Treatment
  • "MRI-Based Digital Models Forecast Patient-Specific Treatment Responses to Neoadjuvant Chemotherapy in Triple-Negative Breast Cancer," 2022, Cancer Research

Their contributions address a range of topics that span both clinical and molecular aspects of cancer treatment and diagnostics:

  • Breast Cancer Treatment Studies
  • HER2/EGFR in Cancer Research
  • Cancer Treatment and Pharmacology
  • Radiomics and Machine Learning in Medical Imaging
  • Cancer Genomics and Diagnostics
  • Advanced Breast Cancer Therapies
  • MRI in cancer diagnosis

Frequent collaborators in their research include:

  • Debu Tripathy
  • Bora Lim
  • Jennifer K. Litton
  • Rosalind P. Candelaria
  • Jason B. White

Vicente Valero's research experience integrates clinical trials, advanced imaging techniques, and molecular diagnostics, contributing to the evolving landscape of breast cancer therapies and personalized medicine.

Best Publications

  • Adjuvant trastuzumab in HER2-positive breast cancer.

    Dennis Slamon;Wolfgang Eiermann;Nicholas Robert;Tadeusz Pienkowski

  • Measurement of Residual Breast Cancer Burden to Predict Survival After Neoadjuvant Chemotherapy

    W. Fraser Symmans;Florentia Peintinger;Christos Hatzis;Radhika Rajan

  • An integrative genomic and proteomic analysis of PIK3CA, PTEN, and AKT mutations in breast cancer.

    Katherine Stemke-Hale;Ana Maria Gonzalez-Angulo;Ana Lluch;Richard M. Neve

  • Characterization of a naturally occurring breast cancer subset enriched in epithelial-to-mesenchymal transition and stem cell characteristics.

    Bryan T. Hennessy;Ana Maria Gonzalez-Angulo;Katherine Stemke-Hale;Michael Z. Gilcrease

  • Phase III Randomized Trial Comparing Doxorubicin and Cyclophosphamide Followed by Docetaxel (AC→T) with Doxorubicin and Cyclophosphamide Followed by Docetaxel and Trastuzumab (AC→TH) with Docetaxel, Carboplatin and Trastuzumab (TCH) in Her2neu Positive Early Breast Cancer Patients: BCIRG 006 Study.

    D. Slamon;W. Eiermann;N. Robert;T. Pienkowski

  • Pharmacogenomic Predictor of Sensitivity to Preoperative Chemotherapy With Paclitaxel and Fluorouracil, Doxorubicin, and Cyclophosphamide in Breast Cancer

    Kenneth R. Hess;Keith Anderson;W. Fraser Symmans;Vicente Valero

  • Differential response to neoadjuvant chemotherapy among 7 triple-negative breast cancer molecular subtypes

    Hiroko Masuda;Keith A. Baggerly;Ying Wang;Ya Zhang

  • Phase II Study of Weekly Docetaxel and Trastuzumab for Patients With HER-2–Overexpressing Metastatic Breast Cancer

    Francisco J. Esteva;Vicente Valero;Daniel Booser;Laura T. Guerra

  • Clinical and Pathologic Characteristics of Patients With BRCA-Positive and BRCA-Negative Breast Cancer

    Deann P. Atchley;Constance T. Albarracin;Adriana Lopez;Vicente Valero

  • Weekly Trastuzumab and Paclitaxel Therapy for Metastatic Breast Cancer With Analysis of Efficacy by HER2 Immunophenotype and Gene Amplification

    Andrew D. Seidman;Monica N. Fornier;Francisco J. Esteva;Lee Tan

  • Prognostic value of pathologic complete response after primary chemotherapy in relation to hormone receptor status and other factors

    Valentina Guarneri;Kristine Broglio;Shu Wan Kau;Massimo Cristofanilli

  • A Genomic Predictor of Response and Survival Following Taxane-Anthracycline Chemotherapy for Invasive Breast Cancer

    Christos Hatzis;Lajos Pusztai;Vicente Valero;Daniel J. Booser

  • Gene expression profiles predict complete pathologic response to neoadjuvant paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide chemotherapy in breast cancer.

    M. Ayers;W.F. Symmans;J. Stec;A.I. Damokosh

  • Neoadjuvant Therapy with Paclitaxel followed by 5-Fluorouracil, Epirubicin, and Cyclophosphamide Chemotherapy and Concurrent Trastuzumab in Human Epidermal Growth Factor Receptor 2–Positive Operable Breast Cancer: An Update of the Initial Randomized Study Population and Data of Additional Patients Treated with the Same Regimen

    Aman U. Buzdar;Vicente Valero;Nuhad K. Ibrahim;Deborah Francis

  • Long-Term Prognostic Risk After Neoadjuvant Chemotherapy Associated With Residual Cancer Burden and Breast Cancer Subtype.

    W. Fraser Symmans;Caimiao Wei;Rebekah Gould;Xian Yu

  • RIBBON-2: A Randomized, Double-Blind, Placebo-Controlled, Phase III Trial Evaluating the Efficacy and Safety of Bevacizumab in Combination With Chemotherapy for Second-Line Treatment of Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer

    Adam M. Brufsky;Sara Hurvitz;Edith Perez;Raji Swamy

  • High risk of recurrence for patients with breast cancer who have human epidermal growth factor receptor 2-positive, node-negative tumors 1 cm or smaller.

    Ana Maria Gonzalez-Angulo;Jennifer K Litton;Kristine R Broglio;Funda Meric-Bernstam

  • Ipatasertib plus paclitaxel versus placebo plus paclitaxel as first-line therapy for metastatic triple-negative breast cancer (LOTUS): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial.

    Sung-Bae Kim;Rebecca Dent;Seock-Ah Im;Marc Espié

  • Weekly Paclitaxel Improves Pathologic Complete Remission in Operable Breast Cancer When Compared With Paclitaxel Once Every 3 Weeks

    Marjorie C. Green;Aman U. Buzdar;Terry Smith;Nuhad K. Ibrahim

  • Outcome After Pathologic Complete Eradication of Cytologically Proven Breast Cancer Axillary Node Metastases Following Primary Chemotherapy

    Bryan T. Hennessy;Gabriel N. Hortobagyi;Roman Rouzier;Henry Kuerer

Frequent Co-Authors

Gabriel N. Hortobagyi
Gabriel N. Hortobagyi The University of Texas MD Anderson Cancer Center
Naoto T. Ueno
Naoto T. Ueno University of Hawaiʻi Cancer Center
Aman U. Buzdar
Aman U. Buzdar The University of Texas MD Anderson Cancer Center
Massimo Cristofanilli
Massimo Cristofanilli Cornell University
Banu Arun
Banu Arun The University of Texas MD Anderson Cancer Center
Wendy A. Woodward
Wendy A. Woodward The University of Texas MD Anderson Cancer Center
Lajos Pusztai
Lajos Pusztai Yale University
Thomas A. Buchholz
Thomas A. Buchholz The University of Texas MD Anderson Cancer Center
Ana M. Gonzalez-Angulo
Ana M. Gonzalez-Angulo The University of Texas MD Anderson Cancer Center
James M. Reuben
James M. Reuben The University of Texas MD Anderson Cancer Center

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Exploring medicine in the USA opens doors to a wide range of online healthcare degrees and career options beyond the traditional MD. Students frequently consider management-focused degrees, such as healthcare administration, to move into leadership roles within hospitals or clinics. Many seek the cheapest mha programs online to gain these essential skills without the burden of high tuition.

Nursing professionals may pursue advanced clinical practice through cheap dnp online programs, earning the Doctor of Nursing Practice and expanding their scope of practice. For those interested in pharmacy, online degree options are increasing, but cost remains a top concern. Prospective pharmacists should carefully compare online pharmacy school cost to select affordable, accredited pathways.

Another fast-growing field is health informatics, connecting healthcare, IT, and data management. There are now numerous programs in health informatics available online, helping students leverage technology to improve patient care. Each of these pathways provides unique opportunities and offers flexible, budget-friendly options for those passionate about healthcare.

Best Scientists Citing Vicente Valero

Trending Scientists

Recently Published Articles